Document is current

Article History

Received: 26 June 2025

Accepted: 29 September 2025

First Online: 21 November 2025

Declarations

:

: All experiments were performed in accordance with the Good Clinical Practice (GCP) guidelines as defined by the International Conference on Harmonization (ICH), and the French regulations in force (i.e., the French Public Health Law N. 2004–806 of August 9, 2004; Loi n. 2004- 806 du 9 août 2004 relative à la politique de santé publique), the Bioethical Laws, the declaration of Helsinki (Appendix 9) and the Informatics and Freedom Law. This study is registered at ClinicalTrials.gov ( : Identifier NCT03252912). It was approved by the Ethics Committee (CPP SUD MEDITERRANEE 13/07/2016, n°2016–05-03 bis). The patient’s written informed consent was obtained before collecting any personal data.

: All contributing authors approve the submission and publication of this manuscript.

: - AD, SL, CH, SP, ML, NP, AA and CD declare no conflict of interest related to this study.- WJ has received fees (Astra Zeneca, Eisai, BMS, Lilly France, Daiichi Sankyo, MSD, Novartis, Pfizer, Roche, Seagen), support for attending meetings/travel (Astra Zeneca, Novartis, Chugai Pharma, Pfizer, Eisai, Pierre Fabre, Glaxo Smithkline, Roche, Lilly France, Sanofi Aventis) and participated on a Data Safety Monitoring Board or Advisory Board (Astra Zeneca, Eisai, BMS, Lilly France, Daiichi Sankyo, MSD, Novartis, Pfizer, Roche, Seagen, Gilead).